Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
GSK to support manufacture of Novavax' COVID-19 vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the […]
Moderna 100 Millionth Dose Shipment of COVID-19 Vaccine to U.S.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
BHF Secure EU Approval for CaRi-Heart®
The first-of-its-kind technology, CaRi-Heart®, was developed by spinout company Caristo Diagnostics and has the power […]
FDA Approves Abecma for Multiple Myeloma
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to […]
New Clues Point to New 'Silent' Stroke Treatments
Scientists have identified new genetic clues in people who’ve had small and often apparently ‘silent’ […]
AZD1222 US Phase III Primary Analysis Confirms Vaccine Safety and Efficacy
76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation […]
New UK Health Security Agency to lead response to future health threats
A new UK Health Security Agency (UKHSA) to plan for, prevent and respond to external […]
Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages
Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential […]
Welsh Startup Antiverse Raises $2m for Antibody Discovery Toolkit
New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its […]
COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
The primary analysis of the Phase III clinical trials from the UK, Brazil and South […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more